NewsSeptember 2009Metabolism in press publication reports that inhibiting LDL glycation with Glycadia’s compound CAP22 ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats. April 2009Clinical and Experimental Pharmacology and Physiology in press publication reports results of first study demonstrating that Glycadia's compound reduces amyloidogenic protein in brain of transgenic mouse model of Alzheimer's disease. October 2008Investigative Ophthalmology & Visual Sciences publication reports on amelioration of diabetes-associated changes in the eye with Glycadia's lead compound. June 2008Results of Glycadia's Phase 1b/2a clinical trial are presented at the Annual Meeting of the American Diabetes Association in San Francisco. May 2007Glycadia presents at Rodman & Renshaw Global Healthcare Conference in Monte Carlo. Glycadia Pharmaceuticals 1880 JFK Blvd, Suite 200 Philadelphia, PA 19103
Tel 215.557.8021 · Fax 215.557.8053 Developing safe and effective treatments for diabetic complications.™ |